EPA-0666 – Long-term maintenance of efficacy of extended-release guanfacine hydrochloride (GXR) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD): double-blind, placebo-controlled, multicentre, phase 3 randomized withdrawal study
Jeffrey H. Newcorn(Mount Sinai Hospital), Brigitte Robertson(Takeda (United States)), A. G. Lyne(University of Manchester), Sasha Sreckovic, Valerie Harpin(Sheffield Children's NHS Foundation Trust), Mats Johnson(Sahlgrenska University Hospital), Ralph Bloomfield(AstraZeneca (United Kingdom)), Judy van Stralen(Ontario Centre of Excellence for Child and Youth Mental Health), Benoît Dutray(Centre hospitalier de Rouffach), Josep Antoni Ramos‐Quiroga(Universitat Autònoma de Barcelona)
Cited by 5
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Computerized Training of Working Memory in Children With ADHD-A Randomized, Controlled Trial
|Journal of the American Academy of Child & Adolescent Psychiatry|2005|2k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder
|Neuroscience & Biobehavioral Reviews|2021|1.4k
Attention-deficit/hyperactivity disorder
|Nature Reviews Disease Primers|2015|1.3k